Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;54(12):2061-2066.
doi: 10.1111/imj.16563. Epub 2024 Nov 11.

Anti-MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Janelle See  1 , Jessica L Fairley  1   2 , Ai L Yeo  1   3 , Samar Ojaimi  3   4 , Eric F Morand  1   3
Affiliations

Anti-MDA5 positivity: describing the frequency and spectrum of clinically evident MDA5 disease

Janelle See et al. Intern Med J. 2024 Dec.

Abstract

To evaluate experience in a tertiary rheumatology service with melanoma differentiation-association-protein-5 (MDA5) disease and testing, patients with positive autoantibody results were reviewed for the presence of clinical disease. Anti-MDA5 positivity was detected in 2% of myositis-specific antibody tests. Of these, 29% did not have features consistent with anti-MDA5 disease. However, when present, MDA5 disease is severe with a high mortality.

Keywords: MDA5 disease; dermatomyositis; interstitial lung disease; rapidly progressive ILD; tofacitinib.

PubMed Disclaimer

References

    1. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al. Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52: 1571–1576.
    1. Nombel A, Fabien N, Coutant F. Dermatomyositis with anti‐MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol 2021; 12: 773352.
    1. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola‐Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM‐140): a retrospective study. J Am Acad Dermatol 2011; 65: 25–34.
    1. Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis‐associated interstitial lung disease. N Engl J Med 2019; 381: 291–293.
    1. Li L, Wang Q, Wen X, Liu C, Wu C, Yang F et al. Assessment of anti‐MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis‐associated interstitial lung disease or rapidly progressive interstitial lung disease. Oncotarget 2017; 8: 76129–76140.

Publication types

LinkOut - more resources